Cellebrite Di Ltd. ( (CLBT) ) has released its Q2 earnings. Here is a breakdown of the information Cellebrite Di Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellebrite DI Ltd., a prominent player in the digital investigative solutions sector, provides advanced tools for digital forensics and intelligence gathering, serving both public and private sectors globally. In its latest earnings report, Cellebrite announced an 18% increase in revenue to $113.3 million and a 21% rise in annual recurring revenue to $418.9 million for the second quarter of 2025. The company also reported a net income of $19.5 million, with a non-GAAP net income of $30.8 million and an adjusted EBITDA of $27.9 million, reflecting a 24.6% margin.
Key highlights from the report include the appointment of Thomas E. Hogan as the new CEO, who emphasized the company’s strategic progress, including the pending acquisition of Corellium, a leader in Arm-based virtualization, and advancements in FedRAMP authorization with the U.S. Department of Justice’s sponsorship. These moves are expected to enhance Cellebrite’s offerings and expand its market reach. Additionally, the company made significant leadership changes, with David Barter stepping in as the new CFO.
Financially, Cellebrite’s performance was strong, with subscription revenue growing by 21% year-over-year to $103.0 million. The company achieved a gross profit margin of 84.4% on a GAAP basis and 85.1% on a non-GAAP basis. The recurring revenue dollar-based net retention rate stood at 120%, indicating robust customer retention and growth.
Looking ahead, Cellebrite remains optimistic about its growth prospects, with expectations of continued revenue and ARR growth for the remainder of 2025. The company’s strategic initiatives and leadership changes are anticipated to drive further innovation and expansion, positioning Cellebrite well for future success.